{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:36Z","timestamp":1793228256829,"version":"4.5.0"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cellimm.2025.105058","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:20:11Z","timestamp":1765592411000},"page":"105058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Vitiligo immunopathogenesis: Insight of immune components and prospects of emerging immunotherapies"],"prefix":"10.1016","volume":"420-421","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8010-2223","authenticated-orcid":false,"given":"Manoj Kumar","family":"Tembhre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajihul Hasan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2025.105058_bb0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archderm.1974.01630060081032","article-title":"Letter: Vitiligo in ancient Indian medicine","volume":"109","author":"Singh","year":"1974","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0010","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-4632.2007.03195.x","article-title":"Vitiligo: the historical curse of depigmentation","volume":"46","author":"Millington","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2025.105058_bb0020","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/jid.2013.432","article-title":"Rab11b mediates melanin transfer between donor melanocytes and acceptor keratinocytes via coupled exo\/endocytosis","volume":"134","author":"Tarafder","year":"2014","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0025","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/jid.2011.413","article-title":"Melanosomes are transferred from melanocytes to keratinocytes through the processes of packaging, release, uptake, and dispersion","volume":"132","author":"Ando","year":"2012","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0030","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/2091334a0","article-title":"Vertebrate epidermal melanin unit","volume":"209","author":"Hadley","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2025.105058_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijwd.2017.11.005","article-title":"Vitiligo: Patient stories, self-esteem, and the psychological burden of disease","volume":"4","author":"Grimes","year":"2018","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.cellimm.2025.105058_bb0040","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0378-6323.32708","article-title":"Vitiligo: compendium of clinico-epidemiological features","volume":"73","author":"Sehgal","year":"2007","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cellimm.2025.105058_bb0055","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jaad.2014.10.042","article-title":"A novel point-of-care in vivo technique for preparation of epidermal cell suspension for transplantation in vitiligo","volume":"72","author":"Gupta","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ced.14061","article-title":"A randomized pilot study to compare hair follicle cell suspensions prepared using trypsin alone versus trypsin in combination with collagenase type I for transplantation in vitiligo","volume":"45","author":"Vashisht","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/ijd.13759","article-title":"Study of efficacy and safety of noncultured, extracted follicular outer root sheath cell suspension transplantation in the management of stable vitiligo","volume":"57","author":"Kumar","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0070","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13555-025-01397-z","article-title":"Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis","volume":"15","author":"Mohammed","year":"2025","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"10.1016\/j.cellimm.2025.105058_bb0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1142\/S2737416524500753","article-title":"Mechanistic Explanation of Activation and Inhibition of Crucial Enzymes Involved in Melanin Production","volume":"24","author":"Suyash","year":"2024","journal-title":"Journal of Computational Biophysics and Chemistry"},{"key":"10.1016\/j.cellimm.2025.105058_bb0090","article-title":"Shipra, Low-Dose Melittin Enhanced Pigment Production Through the Upregulation of Tyrosinase Activity and Dendricity in Melanocytes by Limiting Oxidative Stress: A Therapeutic Implication for Vitiligo","volume":"13","author":"Tembhre","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.cellimm.2025.105058_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bjd.18890","article-title":"Effect of narrowband ultraviolet B treatment on microRNA expression in active nonsegmental generalized vitiligo","volume":"183","author":"Parihar","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00403-025-04113-1","article-title":"Non-coding RNAs (miRNAs - circRNAs - lncRNAs) and genes interact with the regulation of vitiligo","volume":"317","author":"AbdElneam","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0105","series-title":"Vitiligo","first-page":"13","article-title":"Epidemiology, Definitions and Classification","author":"Ta\u00efeb","year":"2010"},{"key":"10.1016\/j.cellimm.2025.105058_bb0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng.2272","article-title":"Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo","volume":"44","author":"Jin","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellimm.2025.105058_bb0115","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/ng.602","article-title":"Common variants in FOXP1 are associated with generalized vitiligo","volume":"42","author":"Jin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellimm.2025.105058_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/jid.1959.49","article-title":"Vitiligo","volume":"32","author":"Lerner","year":"1959","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2133.1994.tb08486.x","article-title":"Neuropeptide and neuronal marker studies in vitiligo","volume":"131","author":"Al'Abadie","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0923-1811(99)00090-0","article-title":"Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions","volume":"23","author":"Wu","year":"2000","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cellimm.2025.105058_bb0135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1046\/j.1523-1747.1999.00756.x","article-title":"Altered gene expression in melanocytes exposed to 4-tertiary butyl phenol (4-TBP): upregulation of the A2b adenosine receptor 1","volume":"113","author":"Le Poole","year":"1999","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0925-4439(94)90027-2","article-title":"Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo","volume":"1226","author":"Schallreuter","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cellimm.2025.105058_bb0145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/1523-1747.ep12335801","article-title":"Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo","volume":"109","author":"Maresca","year":"1997","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-4362.1996.tb01609.x","article-title":"Organ-specific autoantibodies in vitiligo patients and their relatives","volume":"35","author":"Mandry","year":"1996","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0155","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","article-title":"High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo","volume":"188","author":"Ogg","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0160","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0749.2006.00333.x","article-title":"A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo","volume":"19","author":"Dell'anna","year":"2006","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0165","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","article-title":"A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?","volume":"16","author":"Gauthier","year":"2003","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0170","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/jid.2015.25","article-title":"Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo","volume":"135","author":"Wagner","year":"2015","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0175","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.jid.5700700","article-title":"Membrane lipid alterations as a possible basis for melanocyte degeneration in vitiligo","volume":"127","author":"Dell'Anna","year":"2007","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00456842","article-title":"Defective calcium uptake in keratinocyte cell cultures from vitiliginous skin","volume":"280","author":"Schallreuter","year":"1988","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1346-8138.1994.tb03276.x","article-title":"Probable mechanisms of loss of Merkel cells in completely depigmented skin of stable vitiligo","volume":"21","author":"Bose","year":"1994","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdermsci.2013.09.004","article-title":"Coexistence of Langerhans cells activation and immune cells infiltration in progressive nonsegmental vitiligo","volume":"73","author":"Itoi","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cellimm.2025.105058_bb0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00403-018-1830-z","article-title":"Increased tenascin C and DKK1 in vitiligo: possible role of fibroblasts in acral and non-acral disease","volume":"310","author":"Esmat","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaci.2016.10.013","article-title":"Oxidative stress drives CD8(+) T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes","volume":"140","author":"Li","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: A review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0210","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjd.13511","article-title":"Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation","volume":"172","author":"Tembhre","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051040","article-title":"Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2025.105058_bb0220","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/1346-8138.12263","article-title":"Role of macrophage infiltration in successful repigmentation in a new periphery-spreading vitiligo lesion in a male Japanese patient","volume":"40","author":"Oiso","year":"2013","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0225","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.15550","article-title":"Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis","volume":"177","author":"Jacquemin","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0230","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00403-010-1109-5","article-title":"Dendritic cells: ultrastructural and immunophenotypical changes upon nb-UVB in vitiligo skin","volume":"303","author":"Prignano","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0240","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","article-title":"Why treatments do(n't) work in vitiligo: An autoinflammatory perspective","volume":"14","author":"Speeckaert","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.det.2016.11.007","article-title":"Medical and Maintenance Treatments for Vitiligo","volume":"35","author":"Passeron","year":"2017","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.cellimm.2025.105058_bb0250","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0214643","article-title":"The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo","volume":"109","author":"Kemp","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2025.105058_bb0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/1523-1747.ep12276556","article-title":"Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay","volume":"109","author":"Kemp","year":"1997","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0260","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000357807","article-title":"Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study","volume":"228","author":"Ingordo","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0265","doi-asserted-by":"crossref","first-page":"35390","DOI":"10.1074\/jbc.M102391200","article-title":"The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I","volume":"276","author":"Hedstrand","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2025.105058_bb0270","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.12659\/MSM.910515","article-title":"Identification of the Risk HLA-A Alleles and Autoantigen in Han Chinese Vitiligo Patients and the Association of CD8+T Cell Reactivity with Disease Characteristics","volume":"24","author":"Yi","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.cellimm.2025.105058_bb0275","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/jid.2009.207","article-title":"Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library","volume":"130","author":"Waterman","year":"2010","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0280","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/jid.2010.341","article-title":"Vitiligo autoantigen VIT75 is identified as lamin A in vitiligo by serological proteome analysis based on mass spectrometry","volume":"131","author":"Li","year":"2011","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/ijd.IJD_344_18","article-title":"Antimelanocyte Antibodies: A Possible Role in Patients with Vitiligo","volume":"65","author":"El-Gayyar","year":"2020","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0290","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/08916934.2020.1836489","article-title":"Autoimmune response against tyrosinase induces depigmentation in C57BL\/6 black mice","volume":"53","author":"Al Robaee","year":"2020","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cellimm.2025.105058_bb0295","doi-asserted-by":"crossref","first-page":"7617839","DOI":"10.1155\/2021\/7617839","article-title":"The Formation of Melanocyte Apoptotic Bodies in Vitiligo and the Relocation of Vitiligo Autoantigens under Oxidative Stress","volume":"2021","author":"Tian","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0300","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Wa\u0144kowicz-Kali\u0144ska","year":"2003","journal-title":"Lab. Investig."},{"key":"10.1016\/j.cellimm.2025.105058_bb0305","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0310","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/cei.12146","article-title":"Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo","volume":"174","author":"You","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0320","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","article-title":"Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site","volume":"80","author":"van den Wijngaard","year":"2000","journal-title":"Lab. Investig."},{"key":"10.1016\/j.cellimm.2025.105058_bb0325","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0330","first-page":"300","article-title":"Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy","volume":"2","author":"Han","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.cellimm.2025.105058_bb0335","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jid.2019.11.013","article-title":"NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo","volume":"140","author":"Jacquemin","year":"2020","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0340","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0345","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1900027","article-title":"The Role of Memory CD8(+) T Cells in Vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0350","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0355","doi-asserted-by":"crossref","first-page":"1639732","DOI":"10.3389\/fimmu.2025.1639732","article-title":"Targeting the IL-15\/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo","volume":"16","author":"Su","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102868","article-title":"Emerging role of Tissue Resident Memory T cells in vitiligo: From pathogenesis to therapeutics","volume":"20","author":"Shah","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14982","article-title":"Compromised melanocyte survival due to decreased suppression of CD4(+) & CD8(+) resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients","volume":"33","author":"Shah","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0370","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/bjd.18902","article-title":"Phenotype and function of circulating memory T cells in human vitiligo","volume":"183","author":"Martins","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0375","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0380","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/phpp.12719","article-title":"Altered circulating memory T cells in vitiligo cases followed NB-UVB therapy","volume":"38","author":"Lin","year":"2022","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.cellimm.2025.105058_bb0385","article-title":"Discovery of resident memory T cells in inflammatory vitiligo: A case report","volume":"101","author":"Xu","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cellimm.2025.105058_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037513","article-title":"Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo","volume":"7","author":"Lili","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2025.105058_bb0395","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1684\/ejd.2014.2436","article-title":"Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells","volume":"24","author":"Lin","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0400","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0405","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/ijd.17959","article-title":"Regulatory T cell dysregulation in Vitiligo: A meta-analysis and systematic review of immune mechanisms and therapeutic perspectives","volume":"64","author":"Lerner","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0410","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jid.2010.337","article-title":"Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP","volume":"131","author":"Birlea","year":"2011","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0415","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2013.01.035","article-title":"Association of FOXP3 (rs3761548) promoter polymorphism with nondermatomal vitiligo: A study from India","volume":"69","author":"Jahan","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145295","article-title":"Association of FOXP3 and GAGE10 promoter polymorphisms and decreased FOXP3 expression in regulatory T cells with susceptibility to generalized vitiligo in Gujarat population","volume":"768","author":"Giri","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.cellimm.2025.105058_bb0425","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0430","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jisp.2016.10.023","article-title":"Replenishing Regulatory T Cells to Halt Depigmentation in Vitiligo","volume":"18","author":"Le Poole","year":"2017","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.cellimm.2025.105058_bb0435","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellimm.2025.105058_bb0440","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellimm.2025.105058_bb0445","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0450","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","article-title":"Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo","volume":"177","author":"Read","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0455","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1172\/JCI26490","article-title":"Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta","volume":"116","author":"Ostroukhova","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2025.105058_bb0460","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.immuni.2008.02.017","article-title":"Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces","volume":"28","author":"Rubtsov","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2025.105058_bb0465","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ni1180","article-title":"Mechanisms of suppression by suppressor T cells","volume":"6","author":"von Boehmer","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0470","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0475","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.174.4.1783","article-title":"Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism","volume":"174","author":"Gondek","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0480","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2025.105058_bb0485","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0490","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0495","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/187152806778256034","article-title":"Oral tolerance and TGF-beta-producing cells","volume":"5","author":"Faria","year":"2006","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.cellimm.2025.105058_bb0500","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0105-2896.2006.00420.x","article-title":"Interleukin-10-secreting type 1 regulatory T cells in rodents and humans","volume":"212","author":"Roncarolo","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0505","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1286-4579(01)01456-3","article-title":"Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells","volume":"3","author":"Weiner","year":"2001","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cellimm.2025.105058_bb0510","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.4049\/jimmunol.1502352","article-title":"Vitamin C Facilitates Demethylation of the Foxp3 Enhancer in a Tet-Dependent Manner","volume":"196","author":"Sasidharan Nair","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0515","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/08923973.2014.968255","article-title":"Assessment of 1,25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of systemic lupus erythematosus","volume":"37","author":"Lavi Arab","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0520","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/eji.201142317","article-title":"Progesterone suppresses the mTOR pathway and promotes generation of induced regulatory T cells with increased stability","volume":"42","author":"Lee","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0525","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1145697","article-title":"Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid","volume":"317","author":"Mucida","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2025.105058_bb0530","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2025.105058_bb0535","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2025.105058_bb0540","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.1300847","article-title":"Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells","volume":"190","author":"van der Touw","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0545","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.4049\/jimmunol.1301181","article-title":"Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo","volume":"191","author":"Zhang","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111174","article-title":"Harmine and Kaempferol treatment enhances NFATC1 and FOXP3 mediated regulatory T-cells' suppressive capacity in generalized vitiligo","volume":"125","author":"Giri","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2023.110737","article-title":"Altered regulatory T cell-mediated Natural Killer cells suppression may lead to generalized vitiligo","volume":"85","author":"Giri","year":"2024","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0560","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10753-023-01922-2","article-title":"EGR1 Mediated Reduction of Fibroblast Secreted-TGF-\u03b21 Exacerbated CD8(+) T Cell Inflammation and Migration in Vitiligo","volume":"47","author":"Jin","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.cellimm.2025.105058_bb0565","first-page":"3617","article-title":"MicroRNA-155 inhibits the proliferation of CD8+ T cells via upregulating regulatory T cells in vitiligo","volume":"20","author":"Lv","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cellimm.2025.105058_bb0570","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1111\/jcmm.13723","article-title":"HO-1 regulates the function of Treg: Association with the immune intolerance in vitiligo","volume":"22","author":"Zhang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0575","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellimm.2025.105058_bb0580","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"3D-hUMSCs Exosomes Ameliorate Vitiligo by Simultaneously Potentiating Treg Cells-Mediated Immunosuppression and Suppressing Oxidative Stress-Induced Melanocyte Damage","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.cellimm.2025.105058_bb0585","series-title":"Enhancing the wound healing process through local injection of exosomes derived from blood serum: An in vitro and in vivo assessment","first-page":"281","volume":"26","author":"Rasti","year":"2024"},{"key":"10.1016\/j.cellimm.2025.105058_bb0590","doi-asserted-by":"crossref","first-page":"3426717","DOI":"10.1155\/2022\/3426717","article-title":"Decreased GZMB, NRP1, ITPR1, and SERPINB9 Transcripts Lead to Reduced Regulatory T Cells Suppressive Capacity in Generalized Vitiligo Patients","volume":"2022","author":"Giri","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.cellimm.2025.105058_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen Specificity Enhances Disease Control by Tregs in Vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102859","article-title":"Th1-like Treg in vitiligo: An incompetent regulator in immune tolerance","volume":"131","author":"Chen","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cellimm.2025.105058_bb0605","first-page":"1219","article-title":"Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance","volume":"148","author":"Le Poole","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0610","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2230.2009.03617.x","article-title":"Macrophage migration inhibitory factor in patients with vitiligo and relationship between duration and clinical type of disease","volume":"35","author":"Serarslan","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152383","article-title":"Ubiquitin-specific protease 34 in macrophages limits CD8 T cell-mediated onset of vitiligo in mice","volume":"228","author":"Li","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0620","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.6073","article-title":"MIF inhibition alleviates vitiligo progression by suppressing CD8(+) T cell activation and proliferation","volume":"260","author":"Chen","year":"2023","journal-title":"J. Pathol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0625","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11845-025-03966-9","article-title":"Macrophage migration inhibitory factor (rs755622) gene polymorphism in vitiligo","volume":"194","author":"Hadi","year":"2025","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.cellimm.2025.105058_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156516","article-title":"Macrophage inhibitory factor alters the functionality of macrophages and their involvement in disease pathogenesis of active generalized vitiligo patients","volume":"176","author":"Sain","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2025.105058_bb0635","doi-asserted-by":"crossref","first-page":"2440377","DOI":"10.1155\/2023\/2440377","article-title":"Increased Expression of Long Noncoding RNA LOC100506314 in T cells from Patients with Nonsegmental Vitiligo and Its Contribution to Vitiligo Pathogenesis","volume":"2023","author":"Lai","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cellimm.2025.105058_bb0640","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CCID.S420385","article-title":"Erzhiwan Ameliorates Restraint Stress- and Monobenzone-Induced Depigmentation in Mice by Inhibiting Macrophage Migration Inhibitory Factor and 8-Hydroxy-2-Deoxyguanosine","volume":"17","author":"Tang","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0645","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1111\/bph.70103","article-title":"Galangin alleviates vitiligo by targeting ANXA2 degradation in macrophages","volume":"182","author":"Wei","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0650","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2025.105058_bb0655","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/bjd\/ljaf041","article-title":"Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in nonsegmental vitiligo","volume":"193","author":"Gay-Mimbrera","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110300","article-title":"Abnormal metabolism in melanocytes participates in the activation of dendritic cell in halo nevus","volume":"265","author":"Jiang","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0665","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.jid.2024.03.036","article-title":"IL-12\/IL-23-Independent Function of BATF3-Dependent Dendritic Cells Is Required for Initiation of Disease in a Mouse Model of Vitiligo","volume":"144","author":"Frisoli","year":"2024","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0670","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00403-022-02343-1","article-title":"Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI","volume":"315","author":"Kim","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0675","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2025.105058_bb0680","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0685","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2008.09.048","article-title":"The role of helper and regulatory T cells in the pathogenesis of vitiligo","volume":"60","author":"Basak","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0690","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/exd.13773","article-title":"Role of IL-17A receptor blocking in melanocyte survival: A strategic intervention against vitiligo","volume":"28","author":"Bhardwaj","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0695","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cyto.2016.12.014","article-title":"Increased systemic and epidermal levels of IL-17A and IL-1\u03b2 promotes progression of non-segmental vitiligo","volume":"91","author":"Bhardwaj","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2025.105058_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052298","article-title":"Increased Tumor Necrosis Factor (TNF)-\u03b1 and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo","volume":"7","author":"Laddha","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2025.105058_bb0705","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/10715762.2017.1402303","article-title":"Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo","volume":"51","author":"Mitra","year":"2017","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0710","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0715","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ced.12464","article-title":"Interleukin-33 affects cytokine production by keratinocytes in vitiligo","volume":"40","author":"Li","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0720","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ijd.12392","article-title":"Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo","volume":"54","author":"Vaccaro","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0725","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00403-016-1675-2","article-title":"IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo","volume":"308","author":"Vaccaro","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0730","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0735","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0740","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","article-title":"Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8(+) T cells activation via JAK-STAT pathway in vitiligo","volume":"139","author":"Chen","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0745","doi-asserted-by":"crossref","first-page":"eadd8454","DOI":"10.1126\/sciimmunol.add8454","article-title":"Tissue-resident memory T cell maintenance during antigen persistence requires both cognate antigen and interleukin-15","volume":"8","author":"Tieu","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0750","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.1402a69","article-title":"Serum Levels of IL-35, One of the Newest Members of Interleukin-12 Family of Cytokines, in Patients With Vitiligo","volume":"14","author":"Hayran","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"10.1016\/j.cellimm.2025.105058_bb0755","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cytogfr.2015.07.003","article-title":"Interleukin-12: Functional activities and implications for disease","volume":"26","author":"Zundler","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0760","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cytogfr.2015.07.008","article-title":"The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity","volume":"26","author":"Aparicio-Siegmund","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156732","article-title":"The potential therapeutic role of IL-35 in pathophysiological processes in type 1 diabetes mellitus","volume":"182","author":"Bakery","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2025.105058_bb0770","article-title":"Evaluation of IL-38, a Newly-introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features","volume":"14","author":"Zarrabi","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"10.1016\/j.cellimm.2025.105058_bb0775","doi-asserted-by":"crossref","DOI":"10.1111\/phpp.12947","article-title":"The correlation analysis between alterations of serum vitamin D, IL-33 levels, and clinical improvement after narrow-band UVB treatment in vitiligo patients: A case-control study","volume":"40","author":"Soyer","year":"2024","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.cellimm.2025.105058_bb0780","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2023.08.006","article-title":"ISG15-USP18 Dysregulation by Oxidative Stress Promotes IFN-\u03b3 Secretion from CD8+ T cells in Vitiligo","volume":"144","author":"Lee","year":"2024","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0785","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/pcmr.12978","article-title":"Presence and the roles of IL-9\/Th9 axis in vitiligo","volume":"34","author":"Kumar","year":"2021","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0790","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/13685538.2020.1806814","article-title":"Levels of TNF-\u03b1, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo, The aging male : the official journal of the International Society for the Study of the","volume":"23","author":"Karag\u00fcn","year":"2020","journal-title":"Aging Male"},{"key":"10.1016\/j.cellimm.2025.105058_bb0795","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jid.2017.03.020","article-title":"CXCL12 as a Predictor of Vitiligo Activity and Disease Progression","volume":"137","author":"Alexeev","year":"2017","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0800","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.autrev.2017.07.006","article-title":"Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis","volume":"16","author":"Ferrari","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0805","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0810","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0815","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jid.2016.12.028","article-title":"Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression","volume":"137","author":"Rezk","year":"2017","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0820","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0825","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1346-8138.14004","article-title":"Role of chemokines and the corresponding receptors in vitiligo: A pilot study","volume":"45","author":"Yang","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0835","doi-asserted-by":"crossref","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.120027","article-title":"Rubia cordifolia L. extract ameliorates vitiligo by inhibiting the CXCL10\/CXCL9\/STAT1 signaling pathway","volume":"350","author":"Xia","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0845","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.freeradbiomed.2024.10.303","article-title":"Increased splicing of CXCR3 isoform B (CXCR3B) by impaired NRF2 signaling leads to melanocyte apoptosis in active vitiligo","volume":"225","author":"Le","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb0850","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/exd.14732","article-title":"DCUN1D1, a new molecule involved in depigmentation via upregulating CXCL10","volume":"32","author":"Zhao","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0855","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jid.2022.05.1090","article-title":"Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo","volume":"142","author":"Essien","year":"2022","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0860","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250281","article-title":"The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment","volume":"54","author":"Liu","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0865","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/iid3.423","article-title":"CCL17-CCR4 axis contributes to the onset of vitiligo in mice","volume":"9","author":"Li","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.cellimm.2025.105058_bb0870","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00403-021-02228-9","article-title":"Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome","volume":"314","author":"El-Domyati","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0875","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1080\/07391102.2023.2242952","article-title":"Identifying potential inhibitors of C-X-C motif chemokine ligand10 against vitiligo: structure-based virtual screening, molecular dynamics simulation, and principal component analysis","volume":"42","author":"Khan","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.cellimm.2025.105058_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114364","article-title":"Interleukin 1\u03b1 and interleukin 18 in patients with vitiligo - Results of a case-control study","volume":"160","author":"Nieradko-Iwanicka","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cellimm.2025.105058_bb0885","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-4632.2006.02744.x","article-title":"Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo","volume":"45","author":"Birol","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0890","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00403-019-01996-9","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Gholijani","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0895","doi-asserted-by":"crossref","first-page":"5693572","DOI":"10.1155\/2020\/5693572","article-title":"Increased Serum Levels of IFN-\u03b3, IL-1\u03b2, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo","volume":"2020","author":"Tomaszewska","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.cellimm.2025.105058_bb0900","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0019-5154.92668","article-title":"Serum concentration of IL-6, IL-2, TNF-\u03b1, and IFN\u03b3 in Vitiligo patients","volume":"57","author":"Singh","year":"2012","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0905","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo-New insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0910","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/ijd.IJD_300_20","article-title":"The Study of Serum Level of Interleukin-2, Interleukin-6, and Tumor Necrosis Factor-alpha in Stable and Progressive Vitiligo Patients from Sina Hospital in Tabriz, Iran","volume":"66","author":"Ranjkesh","year":"2021","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0915","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8976.1","article-title":"Recent advances in understanding vitiligo","volume":"5","author":"Manga","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.cellimm.2025.105058_bb0920","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/1523-1747.ep12460991","article-title":"Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis","volume":"96","author":"Swope","year":"1991","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0925","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijd.ijd_27_22","article-title":"A Cross-Sectional Study of the Levels of Cytokines IL-6, TNF-\u03b1, and IFN-\u03b3 in Blood and Skin (Lesional and Uninvolved) of Vitiligo Patients and their Possible Role as Biomarkers","volume":"68","author":"De","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0930","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/pcmr.12667","article-title":"CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study","volume":"31","author":"Abdallah","year":"2018","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0935","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0923-1811(02)00151-2","article-title":"Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo","volume":"31","author":"Tu","year":"2003","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cellimm.2025.105058_bb0940","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1523-1747.ep12289743","article-title":"Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo","volume":"108","author":"Yu","year":"1997","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0945","doi-asserted-by":"crossref","DOI":"10.1097\/JD9.0000000000000234","article-title":"Increased Expression of Serum Monocyte Chemoattractant Protein-1, Chemokine (C-C motif) Ligand 3, and Interleukins in Patients With Vitiligo","volume":"7","author":"Zhao","year":"2024","journal-title":"International Journal of Dermatology and Venereology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0950","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ced.12164","article-title":"Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo","volume":"39","author":"Miniati","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0955","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/jid.2012.181","article-title":"Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8","volume":"132","author":"Toosi","year":"2012","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb0960","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15177","article-title":"Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses","volume":"33","author":"Peeva","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0965","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0970","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2133.2009.09217.x","article-title":"Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus","volume":"161","author":"Taher","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0975","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/423490","article-title":"Association of IFN-\u03b3: IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis","volume":"2015","author":"Ala","year":"2015","journal-title":"Autoimmune diseases"},{"key":"10.1016\/j.cellimm.2025.105058_bb0980","doi-asserted-by":"crossref","DOI":"10.4103\/cdr.cdr_1_23","article-title":"Role of Serum IFN-\u03b3 and IL-10 as Predictive Biomarkers of Vitiligo Disease Activity: A Case-Control Study","volume":"8","author":"Desai","year":"2024","journal-title":"Clinical Dermatology Review"},{"key":"10.1016\/j.cellimm.2025.105058_bb0985","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00403-020-02168-w","article-title":"Dendritic cells sub-sets are associated with inflammatory cytokine production in progressive vitiligo disease","volume":"313","author":"Srivastava","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb0990","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb0995","doi-asserted-by":"crossref","first-page":"5524566","DOI":"10.1155\/2021\/5524566","article-title":"Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo","volume":"2021","author":"Le","year":"2021","journal-title":"Dermatol. Res. Pract."},{"key":"10.1016\/j.cellimm.2025.105058_bb1000","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1111\/jocd.15329","article-title":"Unraveling the relation between vitiligo, Interleukin 17, and serum amyloid A","volume":"21","author":"Ahmed","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1005","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jid.2020.12.021","article-title":"The Role of CXCL10 and IL-18 as Markers of Repigmentation Response in Nonsegmental Vitiligo Treated with Narrowband UVB Phototherapy: A Prospective Cohort Study","volume":"141","author":"Hojman","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1010","first-page":"11429","volume":"22","author":"Custurone","year":"2021","journal-title":"Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments"},{"key":"10.1016\/j.cellimm.2025.105058_bb1015","doi-asserted-by":"crossref","first-page":"109161","DOI":"10.18632\/oncotarget.22644","article-title":"Interleukin-22 participates in the inflammatory process of vitiligo","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2025.105058_bb1020","first-page":"242","article-title":"Serum Interleukin 23 and Nitric Oxide in Vitiligo: New insights into the emerging association with VASI","volume":"29","author":"Bessar","year":"2023","journal-title":"Score %J Zagazig University Medical Journal"},{"key":"10.1016\/j.cellimm.2025.105058_bb1025","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.abd.2020.02.005","article-title":"Decreased levels of interleukin 27 in the serum of vitiligo patients","volume":"95","author":"Hosseini","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155432","article-title":"Tumor Necrosis Factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo","volume":"140","author":"Singh","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2025.105058_bb1035","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.4238\/2013.July.8.1","article-title":"Tumor necrosis factor-\u03b1 and -\u03b2 genetic polymorphisms as a risk factor in Saudi patients with vitiligo","volume":"12","author":"Al-Harthi","year":"2013","journal-title":"Genetics and molecular research : GMR"},{"key":"10.1016\/j.cellimm.2025.105058_bb1040","article-title":"Skin Interstitial Fluid and Plasma Multiplex Cytokine Analysis Reveals IFN-\u03b3 Signatures and Granzyme B as Useful Biomarker for Activity","volume":"13","author":"Ng","year":"2022","journal-title":"Severity and Prognosis Assessment in Vitiligo, Frontiers in immunology"},{"key":"10.1016\/j.cellimm.2025.105058_bb1045","first-page":"217","volume":"12","author":"Jin","year":"2023","journal-title":"Pathogenic Th2 Cytokine Profile Skewing by IFN-\u03b3-Responding Vitiligo Fibroblasts via CCL2\/CCL8"},{"key":"10.1016\/j.cellimm.2025.105058_bb1050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.15570\/actaapa.2015.11","article-title":"Assessment of serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) among non-segmental vitiligo patients: a pilot study","volume":"24","author":"Abdellatif","year":"2015","journal-title":"Acta dermatovenerologica Alpina, Pannonica, et Adriatica"},{"key":"10.1016\/j.cellimm.2025.105058_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156810","article-title":"Unraveling the causal associations between systemic cytokines and six inflammatory skin diseases","volume":"185","author":"Liu","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2025.105058_bb1060","first-page":"589","volume":"58","author":"Elmasry","year":"2019","journal-title":"Cutaneous expression of thymic stromal lymphopoietin (TSLP) in vitiligo patients: a case-control study"},{"key":"10.1016\/j.cellimm.2025.105058_bb1065","volume":"6","author":"Rashighi","year":"2014","journal-title":"CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo"},{"key":"10.1016\/j.cellimm.2025.105058_bb1070","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","article-title":"Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2025.105058_bb1075","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/DAD.0000000000002774","article-title":"Immunohistochemical Expression of CXCL 10 in Vitiligo","volume":"46","author":"Abdelmonem","year":"2024","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4103\/ijd.ijd_925_22","article-title":"The Effect of Transplantation of Cultured Autologous Melanocytes on CXCL9, CXCL10 and CXCL11 Expressions in Vitiligo","volume":"68","author":"Xu","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1085","doi-asserted-by":"crossref","first-page":"8796735","DOI":"10.1155\/2022\/8796735","article-title":"The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response","volume":"2022","author":"He","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.cellimm.2025.105058_bb1090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.25259\/IJDVL_793_2023","article-title":"Differential expression of serum CXCL9 and CXCL10 levels in vitiligo patients and their correlation with disease severity and stability: A cross-sectional study","volume":"91","author":"Aulakh","year":"2025","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1095","first-page":"27","article-title":"Chemokines in Vitiligo Pathogenesis: CXCL10 and 12","volume":"14","author":"Gharib","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1100","doi-asserted-by":"crossref","first-page":"1112811","DOI":"10.3389\/fimmu.2023.1112811","article-title":"A meta-analysis of chemokines in vitiligo: Recruiting immune cells towards melanocytes","volume":"14","author":"Speeckaert","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1105","series-title":"Comprehensive single-cell transcriptomic reveals different destinies of melanocytes and dynamic changes of immune microenvironment in a psychological stress-induced leukoderma and leukotrichia mouse model, Molecular medicine (Cambridge, Mass.)","first-page":"186","volume":"31","author":"Cao","year":"2025"},{"key":"10.1016\/j.cellimm.2025.105058_bb1110","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1097\/CM9.0000000000001689","article-title":"Pro-pigmentary action of 5-fluorouracil through the stimulated secretion of CXCL12 by dermal fibroblasts","volume":"134","author":"Liao","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.cellimm.2025.105058_bb1115","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.jid.2017.02.012","article-title":"Alterations of CXCL12 in Serum of Patients with Vitiligo","volume":"137","author":"Speeckaert","year":"2017","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb1120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.intimp.2017.08.012","article-title":"CCL28 chemokine: An anchoring point bridging innate and adaptive immunity","volume":"51","author":"Mohan","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00403-025-03829-4","article-title":"Gene and tissue expression of CCL13 in vitiligo patients: correlation with disease activity and severity: a case control study","volume":"317","author":"Morad","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb1130","doi-asserted-by":"crossref","first-page":"11110","DOI":"10.1038\/s41598-025-95638-y","article-title":"Associations and mediators between vitiligo and cardiovascular diseases: a Mendelian randomization study","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellimm.2025.105058_bb1135","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb1140","doi-asserted-by":"crossref","first-page":"eabd8995","DOI":"10.1126\/scitranslmed.abd8995","article-title":"Harris, scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in T(reg) function","volume":"13","author":"Gellatly","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb1145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/JD9.0000000000000234","article-title":"Increased expression of serum monocyte chemoattractant protein-1, chemokine (C-C motif) ligand 3, and Iinterleukins in patients with Vitiligo","volume":"7","author":"Zhao","year":"2024","journal-title":"Int. J. Dermatol. Venereol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jdermsci.2018.12.005","article-title":"Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1\/17 cells","volume":"93","author":"Zhang","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cellimm.2025.105058_bb1155","first-page":"3467","article-title":"Serum CCL20 Level in Patients with Vitiligo %J The Egyptian","volume":"85","author":"Elbeah","year":"2021","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb1160","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb1165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1042\/BST20150247","article-title":"Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?","volume":"44","author":"Boardman","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.cellimm.2025.105058_bb1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102761","article-title":"Engineered antigen-specific regulatory T cells for autoimmune skin conditions","volume":"20","author":"Mukhatayev","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb1180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cellimm.2025.105058_bb1185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1190","doi-asserted-by":"crossref","first-page":"290ra287","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2025.105058_bb1195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.autrev.2006.09.013","article-title":"Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?","volume":"6","author":"Bresson","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb1200","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cellimm.2025.105058_bb1205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2013.04.017","article-title":"Tolerogenic dendritic cells as a therapy for treating lupus","volume":"148","author":"Llanos","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1210","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1136\/ard.2009.126383","article-title":"Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis","volume":"69","author":"Harry","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cellimm.2025.105058_bb1215","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.4049\/jimmunol.173.3.1671","article-title":"T cells signaled by NF-kappa B- dendritic cells are sensitized not anergic to subsequent activation","volume":"173","author":"Thompson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1220","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/eji.200839103","article-title":"Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1","volume":"39","author":"Unger","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-1-14","article-title":"Human tolerogenic DC-10: perspectives for clinical applications","volume":"1","author":"Amodio","year":"2012","journal-title":"Transp. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb1230","first-page":"133","article-title":"Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris","volume":"28","author":"Roberti","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.cellimm.2025.105058_bb1235","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1240","series-title":"Comprehensive Overview of Cytokine Interplay in Vitiligo: A Decade of Meta-Analyses Systematically Reviewed, Life (Basel, Switzerland)","volume":"15","author":"Paganelli","year":"2025"},{"key":"10.1016\/j.cellimm.2025.105058_bb1245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","article-title":"Etanercept in the treatment of vitiligo","volume":"215","author":"Rigopoulos","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb1250","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/sj.jid.5700900","article-title":"Impaired PI3K\/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes","volume":"127","author":"Kim","year":"2007","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb1255","first-page":"126","article-title":"Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo, Journal of Psoriasis and Psoriatic","volume":"3","author":"Katz","year":"2018","journal-title":"Arthritis"},{"key":"10.1016\/j.cellimm.2025.105058_bb1260","article-title":"Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria","volume":"8","author":"Wilson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2025.105058_bb1265","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ja.2011.64","article-title":"Ganodermycin, a novel inhibitor of CXCL10 expression from Ganoderma applanatum","volume":"64","author":"Jung","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.cellimm.2025.105058_bb1270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2025.105058_bb1275","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41590-022-01140-2","article-title":"Catch and release: freeing up PD-L1 ameliorates autoimmunity","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1280","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/exd.13952","article-title":"Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity","volume":"28","author":"Rahimi","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1285","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/exd.14500","article-title":"IFN-\u03b3-induced PD-L1 expression on human melanocytes is impaired in vitiligo","volume":"31","author":"Willemsen","year":"2022","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1290","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S267433","article-title":"Research Status and Outlook of PD-1\/PD-L1 Inhibitors for Cancer Therapy","volume":"14","author":"Ai","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cellimm.2025.105058_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.cellimm.2025.105058_bb1300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.579022","article-title":"Targeting the PD-1\/PD-L1 Axis in Human Vitiligo","volume":"11","author":"Willemsen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12026-015-8632-6","article-title":"Participation of T cell immunoglobulin and mucin domain-3 (TIM-3) and its ligand (galectin-9) in the pathogenesis of active generalized vitiligo","volume":"62","author":"Tembhre","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cellimm.2025.105058_bb1310","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J. investigative Dermatology"},{"key":"10.1016\/j.cellimm.2025.105058_bb1315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaad.2016.06.015","article-title":"A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo","volume":"76","author":"Vanderweil","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1320","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cellimm.2025.105058_bb1325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellimm.2025.105058_bb1330","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:59:27Z","timestamp":1771707567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874925001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":266,"alternative-id":["S0008874925001443"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.105058","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo immunopathogenesis: Insight of immune components and prospects of emerging immunotherapies","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.105058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105058"}}